Pibrentasvir
An antiviral medication used in the treatment of hepatitis C
| Pibrentasvir | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Pibrentasvir is an antiviral drug used in combination with other medications for the treatment of hepatitis C virus (HCV) infection. It is a component of the fixed-dose combination drug Glecaprevir/pibrentasvir, marketed under the brand name Mavyret.
Mechanism of Action[edit | edit source]
Pibrentasvir is a NS5A inhibitor, which means it targets the nonstructural protein 5A (NS5A) of the hepatitis C virus. NS5A is essential for viral replication and assembly, and by inhibiting this protein, pibrentasvir disrupts the life cycle of the virus, thereby reducing viral load in the patient's body.
Pharmacokinetics[edit | edit source]
Pibrentasvir is administered orally and is highly bioavailable. It is extensively metabolized in the liver and excreted primarily in the feces. The drug has a long half-life, allowing for once-daily dosing when used in combination with other antiviral agents.
Clinical Use[edit | edit source]
Pibrentasvir is used in combination with glecaprevir, a NS3/4A protease inhibitor, to treat adults with chronic hepatitis C virus infection. This combination is effective against all major genotypes of HCV, making it a pan-genotypic treatment option. The typical treatment duration is 8 to 12 weeks, depending on the patient's prior treatment history and the presence of cirrhosis.
Side Effects[edit | edit source]
Common side effects of pibrentasvir, when used in combination with glecaprevir, include headache, fatigue, and nausea. Serious side effects are rare but may include liver enzyme elevations and hypersensitivity reactions.
Contraindications[edit | edit source]
Pibrentasvir is contraindicated in patients with severe hepatic impairment (Child-Pugh C) and in those with known hypersensitivity to the drug or any of its components. Caution is advised when used in patients with moderate hepatic impairment (Child-Pugh B).
Related pages[edit | edit source]
Pibrentasvir
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
